Prostate Cancer
Too much calcium in blood may increase risk of fatal prostate cancer
|
|
Men who have too much calcium in their bloodstreams may have an increased risk of fatal prostate cancer, according to a new analysis from Wake Forest University School of Medicine and the University of Wisconsin.
“We show that men in upper range of the normal distribution of serum calcium subsequently have an almost three-fold increased risk for fatal prostate cancer,” said Gary G. Schwartz, Ph.D., associate professor of cancer biology and of epidemiology and prevention at Wake Forest, a part of Wake Forest University Baptist Medical Center. Such excess calcium can be lowered, he said.
The research appears in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Racial differences again seen in prostate cancer
|
|
Black men with prostate cancer, compared with their White counterparts, have a poorer prognosis that is not fully explained by other “co-morbid” illnesses, or by different screening rates or access to healthcare, researchers from the UK report.
The finding stems from a systematic review and pooled analysis of 48 published studies that reported Black-White differences in prostate cancer prognosis.
“Some of the differences in prostate cancer mortality may reflect less aggressive management amongst Black men, particularly in older cohorts,” Dr. Yoav Ben-Shlomo from the University of Bristol and colleagues suggest in a report in the International Journal of Cancer.
Obesity ups a woman’s pancreatic cancer risk: study
|
|
Obese women who carry most of their extra weight around the stomach are 70 percent more likely to develop pancreatic cancer, an international team of researchers reported on Tuesday.
The findings suggest are some of the first evidence that the link between obesity and pancreatic cancer is as strong in women as in men, Juhua Luo of Sweden’s Karolinska Institute and colleagues reported in the British Journal of Cancer.
“We found that the risk of developing pancreatic cancer was significantly raised in obese postmenopausal women who carry most of their excess weight around the stomach,” she said in a statement.
Elevated biomarkers predict risk for prostate cancer recurrence
|
|
A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.
Calling their findings a major step forward in prostate cancer care, Texas researchers report in the June 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, that the presence of seven of these biomarkers can predict prostate cancer risk with 86.6 percent reliability. This is at least 15 percentage points higher than standard clinical measures currently in use, the researchers say.
“We have been looking at these biomarkers for the past 10 to 15 years in the laboratory, but now we can translate these findings into progress for the individual patient,” said Shahrokh F. Shariat, M.D., chief resident in urology at the University of Texas Southwestern Medical Center.
Healthy lifestyle triggers genetic changes: study
|
|
Comprehensive lifestyle changes, including a better diet and more exercise, can lead not only to a better physique but also to swift and dramatic changes at the genetic level, U.S. researchers said on Monday.
In a small study, the researchers tracked 30 men with low-risk prostate cancer who decided against conventional medical treatment such as surgery and radiation or hormone therapy.
The men underwent three months of major lifestyle changes, including eating a diet rich in fruits, vegetables, whole grains, legumes and soy products, moderate exercise such as walking for half an hour a day, and an hour of daily stress management methods such as meditation.
Dehydrated Tomatoes Show Promise for Preventing Prostate Cancer
|
|
New research suggests that the form of tomato product one eats could be the key to unlocking its prostate cancer-fighting potential, according to a report in the June 1 issue of Cancer Research, a journal of the American Association for Cancer Research.
“Processing of many edible plants through heating, grinding, mixing or drying dramatically increases their nutrition value, including their cancer prevention potential. It appears that the greatest protective effect from tomatoes comes by rehydrating tomato powder into tomato paste,” said Valeri V. Mossine, Ph.D., research assistant professor of biochemistry at the University of Missouri.
The protective effect of tomato products against prostate cancer has been suggested in many studies, but researchers remain uncertain about the exact mechanisms. Mossine and colleagues demonstrated that FruHis, an organic carbohydrate present in dehydrated tomato products, exerts a strong protective effect.
Estrogen Helps Drive Distinct, Aggressive Form of Prostate Cancer
|
|
Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.
Estrogen-linked signaling helps drive a discrete and aggressive form of the disease caused by a chromosomal translocation, which in turn results in the fusion of two genes.
“Fifty percent of prostate cancers harbor a common recurrent gene fusion, and we believe that this confers a more aggressive nature to these tumors,” explains study senior author Dr. Mark A. Rubin, professor of pathology and laboratory medicine, and vice chair for experimental pathology at Weill Cornell Medical College. Dr. Rubin is also attending pathologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
New analysis boosts drug’s prostate cancer value
|
|
A new analysis of data from a key prostate cancer study has strengthened the view that a drug that is now sold as a generic may be a valuable weapon to prevent prostate cancer, researchers said on Monday.
The drug is finasteride, formerly sold by Merck and Co as Proscar to treat enlargement of the prostate and now available generically. The drug affects male hormone levels.
The men in the study were taking the drug in a dose of 5 milligrams. In a one milligram dose, finasteride is sold by Merck as the baldness remedy Propecia.
Legislation needed to provide coverage for ED treatment after prostatectomy
|
|
Men who have developed erectile dysfunction (ED) following surgery for prostate cancer usually do not have insurance coverage for ED treatment even though their insurance policies cover surgery for prostate cancer, according to an analysis presented today at the 103rd Annual Scientific Meeting of the American Urological Association. In contrast, federal law requires that insurance companies which cover mastectomy for breast cancer treatment also cover breast reconstruction.
Erectile dysfunction (ED) is a common side effect of radical prostatectomy, though not always permanent, and almost all men experience some degree of ED following this surgery. The impact of ED on self-esteem and body image to prostate cancer patients can be as detrimental as the loss of a breast can be to a woman. However, the Women’s Health and Cancer Rights Act, passed by Congress in 1998, requires that third-party payers who cover mastectomy for breast cancer also cover the costs of breast reconstruction.
“There is compelling evidence that ED treatment leads to improved quality of life for the man and his partner,” said Ira D. Sharlip, M.D., a spokesman for the AUA. Therefore, as in the case of breast reconstruction for women, the cost of ED treatment should most certainly be covered for men.”
Rapid prostate cancer test does not ease anxiety
|
|
The stress and anxiety associated with receiving results of a prostate-specific antigen (PSA) test for prostate cancer is not relieved by using rapid PSA tests, but men still prefer to have their results quickly, results of a study indicate.
Waiting for PSA results often creates anxiety for patients and their families because of the potential implications, researchers explain. Dr. Simon Wilkinson from Weiss Memorial Hospital, Chicago, Illinois and colleagues investigated whether reporting PSA results within 15 minutes of obtaining the blood sample would cause less anxiety to patients than reporting the results 1 or 4 days later.
Prostate cancer deaths fall after screening program
|
|
Prostate cancer deaths fell substantially in the decade after one Austrian state began free PSA screening tests for all men ages 45 to 75, according to a new study.
Researchers found that after the state of Tyrol began a program of free PSA screening and prostate cancer treatment in 1993, the expected death rate from prostate cancer dropped by 54 percent. That compared with a decline of 29 percent in the rest of Austria, where free screening was not available.
The findings, reported in the journal BJU International, suggest that routine PSA testing can save men’s lives—something that has long been an open question.
Study Suggests Diet High in Saturated Fat Contributes to Prostate Cancer Treatment Failure
|
|
In the online version of the International Journal of Cancer, Dr. Sara Strom and associates evaluate the association between saturated fat intake and biochemical failure among men who underwent radical prostatectomy (RP).
A cohort of 390 patients who underwent radical prostatectomy at MD Anderson Cancer Center had a semi-quantitative validated Block food frequency questionnaire modified to their regional diets and completed for the year prior to the diagnosis of prostate cancer. Body mass index (BMI) was also calculated. Clinical and pathological data were abstracted from medical records. Categorical and continual variables were analyzed.
Study raises questions about prostate cancer therapies targeting IGF-1
|
|
Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results especially if a major tumor suppressor gene – p53 – is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.
IGF-1 is a polypeptide hormone that can influence growth, differentiation and survival of cells expressing the type 1 receptor (IGF-1R). Past clinical, epidemiological and experimental studies have strongly implicated IGF-1 as a contributing factor in the natural history of prostate cancer. However, very little has been done to prove absolutely that the expression or activation of the IGF-1 signaling pathway at physiologically relevant levels is sufficient to cause a healthy prostate cell to become a cancer cell.
Norman Greenberg, Ph.D., and colleagues conducted a pair of experiments by manipulating gene expression directly in the epithelial compartment of the mouse prostate gland to better understand the role of IGF-1R. In contrast to studies that correlated elevated levels of IGF-1 with the risk of developing prostate cancer, Greenberg’s research showed that eliminating IGF-1R expression in an otherwise normal mouse prostate caused the cells to proliferate and become hyperplastic. Although persistent loss of IGF-1R expression ultimately induced cell stasis and death, both of these processes are regulated by the tumor suppressor gene p53 that is commonly mutated in human prostate cancers. Hence the researchers hypothesized that tumors with compromised p53 might not respond predictably to therapies targeting IGF1 signaling.
OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
|
|
An Oregon Health & Science University Cancer Institute researcher has identified a protein that is a strong indicator of survival for men with advanced prostate cancer. The C-reactive protein, also known as CRP, is a special type of protein produced by the liver that is elevated in the presence of inflammation.
“This could mean that a simple blood test that is already available could help in clinical decision making and patient counseling. Patients and doctors would know better what to expect from the prostate cancer they are facing,” said Tomasz Beer, M.D., director of the Prostate Cancer Research Program at the OHSU Cancer Institute, associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.
Beer’s research will be published online in the journal Cancer on Monday, April 21.
Aging Men Can Reduce Health Risks Through Physical Activity
|
|
Our results suggest that moderate to vigorous physical activity may reduce the risk of benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS) by as much as 25% relative to a sedentary lifestyle. Although the strength of the association appears to be greater with higher levels of activity, there was a non-significant trend toward a protective effect with even light physical activity. Adjustment for multiple confounders in the studies included in this analysis underscores the independence of the protective effect of physical activity on the BPH/LUTS complex.
The notion that physical activity and other modifiable lifestyle factors may alter the risks and severity of BPH and LUTS challenges traditional etiological paradigms and intimates the need for the development of new pathogenic models for the BPH/LUTS disease complex. The assumption that BPH and LUTS are relatively immutable consequences of aging—driven by a combination of genetic predisposition, androgens, and estrogens—underpins prior models. While genotype and hormones are important components, the relationship of physical activity with BPH/LUTS demands consideration of additional modulators of these processes.
It is possible that physical activity influences prostate growth pathways through alterations in hormone levels. However, we believe a more likely explanation is that physical activity exerts beneficial effects through improved cardiovascular health.
